TECHNOLOGY VIDEO

Elon Musk, Chief Executive of Tesla Motors and SpaceX, smiles during the Reuters Global Technology Summit in San Francisco, June 18, 2013. REUTERS/Stephen Lam
REUTERS GLOBAL TECHNOLOGY SUMMIT

Musk: Time to tackle dealer dispute

Elon Musk, Tesla Motors CEO, tells the Reuters Global Tech Summit that he'll talk to politicians who back local car dealers trying to keep Tesla from selling directly to consumers.  Video 

 

Pictures

Photo

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Photo

Flooding in India

Heavy monsoon rains have swollen several rivers.  Slideshow 

Photo

Celebrity portraits

Up close and personal with famous faces.  Slideshow 

Sponsored Links

Asian stocks tumble on weak China PMI, Fed policy plan

TOKYO - Asian shares tumbled to nine-month lows on Thursday as slowing Chinese manufacturing activity exacerbated sentiment already unnerved by the U.S. Federal Reserve Chairman Ben Bernanke confirming the Fed would begin reducing its stimulus spending later this year.

» More Business News

Start-up to bring test-drive cars to buyers, avoiding dealership

DETROIT - A new company hopes to make the car-buying process easier for consumers and more efficient for dealers by bringing cars to buyers for test drives, avoiding the need to spend hours at a dealership.

» More Small Business News

China denounces EU airline carbon law, seeks talks

BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.

» More Green Business News

GSK completes $3 billion acquisition of Human Genome

LONDON | Fri Aug 3, 2012 2:14am EDT

LONDON (Reuters) - GlaxoSmithKline has completed its $3 billion acquisition of long-time biotech partner Human Genome Sciences, after buying all the outstanding shares for $14.25 each in cash, Britain's biggest drugmaker said on Friday.

The deal secures it full rights to recently launched lupus drug Benlysta and other experimental medicines.

(Reporting by Ben Hirschler)
Health
Deals
Global Deals Review: 2011 Q3
Global Deals Review: 2011 Q2
Global Deals Review
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.